Two Cases of Solitary Corpus Cavernosum Metastasis From Prostate Cancer Detected by 68 Ga-PSMA PET Imaging.

Clin Nucl MedAug 24, 2026 (epub)
Case ReportUrologyNuclear MedicineRadiology (Diagnostic)

Guannan Li, Lixiang Yang, Minggang Su et al.

✦ AI-curated · Sources linked

Case in brief

Two patients with prostate cancer developed rapidly rising PSA after radical prostatectomy, with no prior evidence of metastatic disease. In each, 68 Ga-PSMA PET showed an isolated PSMA-avid nodule in the corpus cavernosum, with SUV max values of 4.46 and 22.46. The findings were interpreted as solitary corpus cavernosum metastases. After salvage radiotherapy, PSA levels declined markedly in both patients.

What made this case unusual

The metastases appeared as isolated nodular lesions in the corpus cavernosum, an extremely rare site and pattern of spread from prostate cancer.

Diagnostic / clinical pearl

In patients with rising PSA after prostatectomy and no known metastases, 68 Ga-PSMA PET may identify atypical isolated metastatic sites, including corpus cavernosum nodules.

Source

PubMed · PMID 42640618

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.